Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 11:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Primary Local Therapy Clear all
Completed Not applicable Interventional

Implementation Science Approach to Enhancing Depression Treatment in Collaborative Depression Care Settings ( DepCare )

NCT05085886
View directory record Official record
Conditions
Depressive Symptoms
Interventions
DepCare, Enhanced Usual Care
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Sep 14, 2026, 11:56 AM EDT
Completed Not applicable Interventional

An Evaluation of Clinical Pharmacist-led Intervention on Clinical Outcomes in Patients With Ischemic Stroke

NCT01876667
View directory record Official record
Conditions
Stroke
Interventions
Intervention (CPCRS) Group, Placebo
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 85 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 14, 2026, 11:56 AM EDT
Recruiting Not applicable Interventional

Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)

NCT06133322
View directory record Official record
Conditions
Hypertension
Interventions
Behavioral: Evidence-based interventions recommended by the 2017 ACC/AHA hypertension clinical guideline
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
1,176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 14, 2026, 11:56 AM EDT
Recruiting Not applicable Interventional

Rural Community Peer Partnerships for Improving Methamphetamine-Associated Heart Failure Screening and Engagement

NCT06461962
View directory record Official record
Conditions
Methamphetamine Use, Heart Failure
Interventions
Treatment as Usual, Telehealth-Cardiology
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 14, 2026, 11:56 AM EDT
Completed Not applicable Interventional

Acupuncture for Vasectomy Pre-procedural Anxiety and Pain Control in the Primary Care Setting

NCT03938415
View directory record Official record
Conditions
Acupuncture, Pain, Postoperative, Vasectomy
Interventions
Acupuncture, Standardized pre-procedure medications
Procedure · Other
Lead sponsor
Matthew Snyder
Federal
Eligibility
25 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Sep 14, 2026, 11:56 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

NCT03197935
View directory record Official record
Conditions
Triple-negative Breast Cancer
Interventions
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Placebo, Nab-paclitaxel, Doxorubicin, Cyclophosphamide, Filgrastim, Pegfilgrastim
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
12
States / cities
Palo Alto, California • Norwalk, Connecticut • Carrollton, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 14, 2026, 11:56 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma

NCT01757626
View directory record Official record
Conditions
Neuroblastoma
Interventions
Hu3F8 With GM-CSF
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 14, 2026, 11:56 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver

NCT00001587
View directory record Official record
Conditions
Liver Neoplasms, Neoplasm Metastasis
Interventions
Isolated hepatic portal and arterial perfusion, Melphalan
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 14, 2026, 11:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Center for Disease Control (CDC) Fax to Quit/Academic Detailing Grant

NCT00989755
View directory record Official record
Conditions
Smoking
Interventions
Fax to Quit (F2Q)
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Sep 14, 2026, 11:56 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

NCT02947685
View directory record Official record
Conditions
HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
Interventions
palbociclib, trastuzumab, pertuzumab, letrozole, Anastrozole, Exemestane, Fulvestrant
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
35
States / cities
San Francisco, California • Washington D.C., District of Columbia • Clearwater, Florida + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 14, 2026, 11:56 AM EDT
Recruiting Phase 3 Interventional

A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

NCT07416526
View directory record Official record
Conditions
Hemophilia A
Interventions
NXT007, Human Coagulation Factor VIII
Combination Product · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Aurora, Colorado • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 14, 2026, 11:56 AM EDT
Active, not recruiting Not applicable Interventional

Pain Self-Management and Treatment Engagement for Patients Taking Opioids

NCT06855732
View directory record Official record
Conditions
Chronic Pain, Opioid Use Disorder, Opioid Misuse and Addiction
Interventions
Usual Care, Pain Self-Management
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
17
States / cities
Baltimore, Maryland • Allison Park, Pennsylvania • Blawnox, Pennsylvania + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 14, 2026, 11:56 AM EDT
Recruiting Not applicable Interventional

Evaluation of Safety and Effectiveness of Primary Hybrid Construct of Mobi-C and ACDF in the Treatment of Two-level Symptomatic Degenerative Disc Disease in the Cervical Spine.

NCT06485206
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
One level Mobi-C and one level fusion
Device
Lead sponsor
Highridge Medical
Industry
Eligibility
22 Years to 69 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Sacramento, California • Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Sep 14, 2026, 11:56 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Getting to Zero Among HHI MSM in the American South

NCT05075967
View directory record Official record
Conditions
HIV Infections
Interventions
Health Access Coalitions, Social Media, Peer Support, Promoting Human Autonomy Support & Empathy (PHASE)
Behavioral
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
15 Years and older · Male only
Enrollment
2,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 14, 2026, 11:56 AM EDT
Completed Not applicable Interventional

A Trial to Evaluate Medically Tailored Meals With Patients With Heart Failure

NCT04289181
View directory record Official record
Conditions
Heart Failure
Interventions
Medically Tailored Meals
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Sep 14, 2026, 11:56 AM EDT
Not listed Phase 3 Interventional

Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors

NCT01204801
View directory record Official record
Conditions
Breast Cancer
Interventions
Focused Microwave Thermotherapy, Chemotherapy (control)
Device · Drug
Lead sponsor
Medifocus, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Sep 14, 2026, 11:56 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

NCT06962800
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
Felzartamab, Tacrolimus, Standard of Care IST
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
16
States / cities
Huntsville, Alabama • Fresno, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 14, 2026, 11:56 AM EDT
Completed Phase 3 Interventional Results available

The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study

NCT02793128
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
Interventions
UGN-101 instillations
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
22
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 14, 2026, 11:56 AM EDT
Completed Not applicable Interventional

Abdominal Wall Block Study

NCT03074240
View directory record Official record
Conditions
Umbilical Hernia, Obesity
Interventions
TAPB Group, RSB Group, conversion to general anesthesia
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Sep 14, 2026, 11:56 AM EDT
Not yet recruiting Not applicable Interventional

Personalized Care for Prenatal Stress Reduction & Prevention of Preterm Birth (PTB) Disparities

NCT06915428
View directory record Official record
Conditions
Preterm Birth Complication, Preterm Birth, Preterm Birth Recurrence, Preeclampsia, Preeclampsia (PE), Hypertensive Disorders of Pregnancy, Support Program, Stress, Resilience, Psychological, Empowerment, Patient, Emotional Stress, Pregnancy, Pregnancy Complications, Pregnancy Induced Hypertension, Neonates and Preterm Infants, Cervical Insufficiency, Social Determinants of Health (SDOH), Cervical Shortening, Disparities in Pregnancy Complications, Disparities, Prenatal Care, Care Coordination
Interventions
Care coordination, Electronic massage, support gift #1, Support gift #2, Support gift #3, Support gift #4, Additional PTBCARE+ support, Stress reduction toolkit - Visit 1 (V1), PTBCARE+ mobile application (app) and website, Sleep, meditation, and Wellness app, Emergency low blood sugar kit, Low dose aspirin (LDA), Visit #2 Stress Reduction Toolkit
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
1,228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 14, 2026, 11:56 AM EDT
Recruiting Phase 1 Interventional

Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

NCT04701645
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Fallopian Tube Cancer Stage IV, Fallopian Tube Cancer Stage III
Interventions
Microdevice
Combination Product
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 14, 2026, 11:56 AM EDT
Completed Early Phase 1 Interventional

Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma

NCT02245997
View directory record Official record
Conditions
Neuroblastoma
Interventions
External beam radiotherapy, proton beam RT
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Months to 18 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 14, 2026, 11:56 AM EDT
Recruiting Phase 3 Interventional

Neoadjuvant Darovasertib in Primary Uveal Melanoma

NCT07015190
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Darovasertib, Primary Local Therapy
Drug · Procedure
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
35
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 14, 2026, 11:56 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)

NCT02138825
View directory record Official record
Conditions
Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2017 · Synced Sep 14, 2026, 11:56 AM EDT